The genetic variations contribute to the occurrence and development of AML, mutations in the receptor tyrosine kinase FMS-Like Tyrosine Kinase-3 (FLT3) are present in about one-third of all the patients with AML [4, 5]. The gene discussed is FLT3; the disease is acute myeloid leukemia.